Related Experiment Video

Updated: Sep 29, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.7K

Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future

Lawrence Kasherman1,2,3, Derrick Ho Wai Siu1,4, Rachel Woodford1,5

  • 1Department of Medical Oncology, St. George Hospital, Kogarah, NSW 2217, Australia.

Cancers
|March 25, 2022
PubMed

Insights

New renal cell carcinoma (RCC) treatments combine angiogenesis inhibitors with immune checkpoint inhibitors. Despite improved outcomes, resistance necessitates novel strategies targeting tumor microenvironment interactions for advanced RCC.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Advanced renal cell carcinoma (RCC) treatments traditionally include angiogenesis inhibitors.
  • Combination regimens with immune checkpoint inhibitors show improved outcomes in RCC.
  • Therapeutic resistance remains a significant challenge, driving the need for novel strategies.

Purpose of the Study:

  • To review synergistic mechanisms of angiogenesis and immunomodulation in the RCC tumor microenvironment.
  • To discuss pre-clinical and clinical evidence for RCC treatment strategies.
  • To explore future opportunities in RCC drug development.

Main Methods:

  • Review of pre-clinical studies on angiogenesis and immunomodulation in RCC.
  • Analysis of clinical trial data for combination therapies in RCC.
  • Exploration of therapeutic resistance mechanisms in RCC.

Main Results:

  • Angiogenesis inhibitors and immune checkpoint inhibitors demonstrate synergistic effects in RCC.
  • Evidence supports combination strategies for both clear-cell and non-clear-cell RCC.
  • Understanding tumor microenvironment interactions is key to overcoming resistance.

Conclusions:

  • Combination therapies targeting angiogenesis and immune responses offer promising avenues for advanced RCC.
  • Further research into synergistic mechanisms can overcome therapeutic resistance.
  • Novel drug development holds potential for improved patient outcomes in RCC.
Keywords:
angiogenesis inhibitordrug resistanceimmunotherapyrenal cell carcinomatargeted therapytumor microenvironment

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.8K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

743

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
699
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
870